Porphyromonas, a potential predictive biomarker of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2018-000374
Abstract: Introduction Pseudomonas aeruginosa pulmonary infections are the primary cause of morbi-mortality in patients with cystic fibrosis (CF). In this cohort study, the objective was to identify candidate biomarkers of P. aeruginosa infection within the airway… read more here.
Keywords: cystic fibrosis; potential predictive; pseudomonas aeruginosa; biomarker ... See more keywords
Evaluation the efficacy of optimized two-step-administration therapy with ceftazidime/avibactam for treating Extensively drug-resistance (XDR) Pseudomonas aeruginosa pulmonary infections: a Pharmacokinetic/pharmacodynamic analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Japanese journal of infectious diseases"
DOI: 10.7883/yoken.jjid.2022.289
Abstract: The objective of this pharmacokinetic (PK)/pharmacodynamic (PD) analysis was to evaluate the efficacy of different dosing regimens of ceftazidime-avibactam (CZA) for the treatment of extensively drug-resistance (XDR) Pseudomonas aeruginosa pulmonary infections by using optimized two-step-administration… read more here.
Keywords: aeruginosa pulmonary; pharmacodynamic analysis; pharmacokinetic pharmacodynamic; ceftazidime avibactam ... See more keywords